Vicki L. Sato - 28 Jun 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Alexander Schuth, by power of attorney
Issuer symbol
DNLI
Transactions as of
28 Jun 2023
Net transactions value
-$49,709
Form type
4
Filing time
30 Jun 2023, 17:21:40 UTC
Previous filing
15 Jun 2023
Next filing
03 Jul 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $16,312 -552 -0.4% $29.55 135,817 28 Jun 2023 Direct F1, F2
transaction DNLI Common Stock Sale $33,398 -1,114 -0.82% $29.98 134,703 28 Jun 2023 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.85 to $29.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.85 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 Includes 4,216 RSUs.